Latest news - Duchenne UK
Clinical Trials Lectureship (Newcastle). End of project report summary
In a new transatlantic collaboration, Duchenne UK and the DMD Hub, PPMD and RTI International are conducting a study to explore attitudes towards gene therapy and gene editing from adults with Duchenne muscular dystrophy (DMD), parents and caregivers of children with DMD, and clinicians.
Read More
Everyone aged 5 and over with DMD eligible for vaccination
The JCVI has confirmed that people aged 5 and over with muscular dystrophy, or who receive high to moderate doses of corticosteroids, are eligible for vaccination against COVID. This includes children aged 5 and over whom they live with.
Read More
Serious adverse event on Pfizer’s Phase 1B gene therapy trial
Last night we heard news from our friends at PPMD in the US that a young man has died while participating in Pfizer’s Phase 1B Open-Label study. Read Pfizer's statement to the community.
Read More
Gene editing start-up secures £3.4 million grant for DMD research
Biotech company MyoGene Bio have received a grant to study innovative gene-editing therapy, thanks to support from Duchenne UK and other charities.
Read More
Mother of Reinvention – Duchenne UK features in The Times
Duchenne UK featured in The Times' Rare Disease report this week, with articles from CEO Emily Reuben and Project HERCULES' Fleur Chandler.
Read More
Festive MINI Electric embarks on charity tour, raising money for Duchenne UK
A MINI Electric wrapped in 2,000 smart Twinkly LED lights is starting a five-week tour to spread festive cheer and raise money for Duchenne UK alongside the MS Trust and Alzheimer’s Society.
Read More
DMD Hub team expands
In the last few months, the DMD Hub has recruited two new staff members to work with Emma Heslop, the DMD Hub Manager, and to look at new areas where the DMD Hub can develop support.
Read More
Data from wearable devices approved for use in Duchenne muscular dystrophy clinical trials
The European Medicines Agency (EMA) has approved the first measure collected using a digital wearable device for use in clinical trials for Duchenne muscular dystrophy.
Read More
TREAT-NMD Statement on Stem Cell Tourism
Treat-NMD, the organisation that represents doctors and scientists working in neuromuscular disease, has released an important statement on stem cell tourism.
Read More